Atrion Co. (NASDAQ:ATRI - Get Free Report) shares saw strong trading volume on Wednesday . 13,511 shares traded hands during mid-day trading, a decline of 18% from the previous session's volume of 16,444 shares.The stock last traded at $410.50 and had previously closed at $409.13.
Wall Street Analyst Weigh In
Separately, StockNews.com upgraded shares of Atrion from a "sell" rating to a "hold" rating in a research note on Friday, March 1st.
Get Our Latest Research Report on ATRI
Atrion Trading Down 2.5 %
The company has a market capitalization of $701.82 million, a PE ratio of 37.21 and a beta of 0.60. The firm has a 50 day simple moving average of $399.68 and a two-hundred day simple moving average of $364.86.
Atrion (NASDAQ:ATRI - Get Free Report) last posted its quarterly earnings data on Thursday, February 29th. The medical instruments supplier reported $3.65 earnings per share for the quarter. The firm had revenue of $43.58 million for the quarter. Atrion had a net margin of 11.46% and a return on equity of 8.07%.
Atrion Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Friday, March 29th. Stockholders of record on Friday, March 15th were issued a $2.20 dividend. This represents a $8.80 annualized dividend and a dividend yield of 2.21%. The ex-dividend date was Thursday, March 14th. Atrion's payout ratio is 79.78%.
Institutional Trading of Atrion
Hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp lifted its holdings in Atrion by 2.2% in the first quarter. Bank of New York Mellon Corp now owns 8,783 shares of the medical instruments supplier's stock valued at $6,263,000 after acquiring an additional 185 shares during the period. MetLife Investment Management LLC boosted its holdings in Atrion by 57.0% during the first quarter. MetLife Investment Management LLC now owns 777 shares of the medical instruments supplier's stock worth $554,000 after buying an additional 282 shares in the last quarter. Bridgewater Associates LP grew its position in Atrion by 28.5% during the first quarter. Bridgewater Associates LP now owns 1,985 shares of the medical instruments supplier's stock worth $1,415,000 after buying an additional 440 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Atrion by 2.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 9,988 shares of the medical instruments supplier's stock valued at $7,122,000 after buying an additional 257 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of Atrion by 22.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,913 shares of the medical instruments supplier's stock valued at $1,364,000 after acquiring an additional 345 shares during the period. 66.19% of the stock is owned by institutional investors and hedge funds.
Atrion Company Profile
(
Get Free Report)
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
Further Reading
Before you consider Atrion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atrion wasn't on the list.
While Atrion currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
